Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Midodrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Midodrine SCHEMBL6033144 | 1.00 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL131436 | 1.00 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL29367411 | 1.00 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| (R)-Midodrine SCHEMBL30917926 | 1.00 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL41463 | 0.99 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899416 | 0.99 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899425 | 0.99 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL29368755 | 0.99 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL41464 | 0.97 | ADRA1A (0.95) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899432 | 0.96 | ADRA1A (0.93) | ADRA1ALMNACYP1A2TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | claimed |
| CN-116381107-B | Method for ultrasonically extracting effective components of astragalus root safflower medicament by using natural eutectic solvent | 浙江中医药大学 | 2025-05-23 | — | — | CN | claimed |
| CN-119950722-A | Application of TRIM44 expression inhibitor in preparation of cytarabine drug-resistant leukemia drug | 柳州市人民医院 | 2025-05-09 | — | — | CN | claimed |
| CN-119776315-A | Enzyme for synthesizing glabridin | 清华大学 | 2025-04-08 | — | — | CN | claimed |
| CN-115068588-B | Application of cytisine effective component in preparing HPV (human papillomavirus) resistant gel | 江西康林药业有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119510609-A | Method for simultaneously measuring low-content active chemical components in tetrandra and astragalus decoction | 南京中医药大学 | 2025-02-25 | — | — | CN | claimed |
| CN-119086768-A | Quality detection method of Anzi brewing soup | 深圳市妇幼保健院 | 2024-12-06 | — | — | CN | claimed |
| EP-4114466-B1 | TREATMENT OF PAIN AND VASOCONSTRICTION | AISA PHARMA INC (US) | 2024-12-04 | — | — | EP | claimed |
| CN-118641656-A | A Chinese medicinal composition for treating heart failure, and its detection method | 上海中医药大学附属曙光医院 | 2024-09-13 | — | — | CN | claimed |
| CN-118345132-A | Biosynthesis method of glabridin precursor 4' -O-Methylpreglabridin | 南京中医药大学 | 2024-07-16 | — | — | CN | claimed |
| EP-0995441-B1 | Combination of compounds for treating erectile dysfunctions | PD DR DUNZENDORFER (DE) | 2002-07-24 | — | — | EP | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| EP-0995441-A2 | Combination of compounds for treating erectile dysfunctions | PD Dr. Dunzendorfer (DE) | 2000-04-26 | — | — | EP | claimed |
| EP-0384266-B1 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LOHMANN THERAPIE SYST LTS (DE) | 1994-07-20 | — | — | EP | claimed |
| EP-0384267-B1 | THERAPEUTIC SYSTEM FOR THE SUSTAINED AND CONTROLLED TRANSDERMAL OR TRANSMUCOSAL DELIVERY OF ACTIVE AGENTS | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1993-05-26 | — | — | EP | claimed |
| EP-0384267-A2 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1990-08-29 | — | — | EP | claimed |
| EP-0384266-A2 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1990-08-29 | — | — | EP | claimed |
| EP-0164571-B1 | SUSTAINED-RELEASE FORMS OF ALPHA-(2,5-DIMETHOXY PHENYL)-BETA-GLYCINAMIDOETHANOL AND PROCESS FOR THEIR PREPARATION | CL PHARMA AKTIENGESELLSCHAFT (AT) | 1990-06-27 | — | — | EP | claimed |
| EP-0164571-A2 | Sustained-release forms of alpha-(2,5-dimethoxy phenyl)-beta-glycinamidoethanol and process for their preparation | CL PHARMA AKTIENGESELLSCHAFT (AT) | 1985-12-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | ADRA1A 1404/4885LMNA 134/4885CYP1A2 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.